Q3 FY2026 · ended Sep 30, 2026 · Revenue $95.28M, +5.7% YoY · Filed Nov 3, 2026
Viskase Holdings, Inc. (VISK) files with the SEC under industry code 2836, Biological Products, (No Diagnostic Substances). In Q3 of fiscal 2026, the quarter ended Sep 30, 2026, it reported revenue of $95.3 million and a net loss of $6.4 million. Free cash flow was -$6.1 million. As of Sep 30, 2026 it held $7.7 million in cash and investments and $290.6 million in total debt.
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- VISK (OTC)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Lombard, IL
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 727510
- Former names
- ENZON PHARMACEUTICALS, INC. (until Mar 25, 2026); ENZON PHARMACEUTICALS INC (until Feb 23, 2016); ENZON PHARMACEUTICALS INC (until Mar 22, 2006); ENZON PHARMACEUTICAL INC (until Dec 10, 2002); ENZON INC (until Dec 9, 2002)
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q3 FY2026 Sep 30, 2026 |
Q2 FY2026 Jun 30, 2026 |
Q1 FY2026 Mar 31, 2026 |
Q4 FY2025 Dec 31, 2025 |
Q3 FY2025 Sep 30, 2025 |
|---|---|---|---|---|---|
| Revenue | $95.3M | $90.1M | $86.5M | — | — |
| Operating income | -$3.1M | -$2.0M | -$4.3M | $20.8M | -$9.1M |
| Net income | -$6.4M | -$5.1M | -$6.7M | $43.4M | -$13.0M |
| Diluted EPS | -$0.45 | -$0.35 | -$0.84 | $0.15 | -$2.40 |
| Operating cash flow | $454,000 | -$11.2M | -$16.3M | -$15.5M | $10.1M |
| Free cash flow | -$6.1M | -$18.9M | -$25.3M | — | — |
| Total assets | $427.5M | $424.5M | $428.9M | $402.1M | $43.7M |
| Stockholders' equity | $178.9M | $186.8M | $192.2M | $145.8M | -$923,000 |
| Cash and investments | $7.7M | $7.9M | $28.6M | $9.2M | $43.3M |
| Total debt | $290.6M | $204.3M | $203.1M | — | — |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 10-Q | Quarterly report | Nov 3, 2026 | Sep 30, 2026 |
| 10-Q | Quarterly report | Aug 3, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Material agreement, Change to shareholder rights, Bylaw or fiscal year change, Regulation FD disclosure
|
May 5, 2026 | Apr 30, 2026 |
| 10-Q | Quarterly report | May 4, 2026 | Mar 31, 2026 |
| 8-K/A | Amended current report | May 1, 2026 | Mar 26, 2026 |
| 8-K |
Current report
Officer or director change
|
May 1, 2026 | Apr 29, 2026 |
All 1000 Viskase Holdings, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.